Exchange Traded Concepts LLC Grows Position in Illumina, Inc. (NASDAQ:ILMN)

Exchange Traded Concepts LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 54.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 220,691 shares of the life sciences company's stock after buying an additional 77,643 shares during the period. Exchange Traded Concepts LLC owned 0.14% of Illumina worth $17,510,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fourth Dimension Wealth LLC bought a new stake in Illumina during the 4th quarter worth approximately $40,000. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina during the 4th quarter valued at $45,000. Assetmark Inc. increased its holdings in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the period. Lee Danner & Bass Inc. purchased a new stake in shares of Illumina in the fourth quarter worth $48,000. Finally, V Square Quantitative Management LLC raised its position in shares of Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock worth $52,000 after buying an additional 132 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of a number of research analyst reports. Citigroup decreased their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Morgan Stanley cut their price objective on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Barclays lowered their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research note on Thursday, April 10th. Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Royal Bank of Canada decreased their price target on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, nine have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.94.

Illumina Trading Down 1.4%

ILMN traded down $1.20 on Friday, hitting $86.93. 1,612,726 shares of the company were exchanged, compared to its average volume of 2,282,496. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a fifty day simple moving average of $79.08 and a two-hundred day simple moving average of $102.64. The stock has a market capitalization of $13.76 billion, a PE ratio of -11.32, a price-to-earnings-growth ratio of 1.60 and a beta of 1.32. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the prior year, the firm posted $0.98 earnings per share. The business's quarterly revenue was down 1.4% compared to the same quarter last year. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Activity at Illumina

In related news, CFO Ankur Dhingra purchased 6,100 shares of the business's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the acquisition, the chief financial officer now directly owns 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.